Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegetron prospective Optimal Weight-based dosing Response program

Trial Profile

Pegetron prospective Optimal Weight-based dosing Response program

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2016

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms POWeR
  • Sponsors Schering Canada
  • Most Recent Events

    • 06 Feb 2016 Results (post hoc pooled analysis of PoWer and RediPEN studies) published in the European Journal of Clinical Microbiology and Infectious Diseases (n = 1242).
    • 02 Nov 2010 Results reported at AASLD, according to a Biolex Therapeutics media release.
    • 02 Nov 2009 Results have been presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top